TRX 813
Alternative Names: TRX-813Latest Information Update: 30 Mar 2025
At a glance
- Originator TRx Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Cancer
Most Recent Events
- 17 Feb 2025 Unspecified in Cancer in United Kingdom (PO) (TRx Biosciences pipeline; February 2025)